Unlocking Latin American Opportunities with Streamlined COFEPRIS Approvals
The Mexican healthcare market, a vibrant and expanding landscape, is poised for a significant transformation with the introduction of new regulatory guidelines by the Federal Commission for the Protection against Sanitary Risks (COFEPRIS). Published in the Diario Oficial de la Federación on July 18, 2025, these guidelines establish an abbreviated regulatory pathway for health supplies, marking a pivotal moment for international pharmaceutical and medical device companies looking to enter or expand within Latin America .
The Essence of the New COFEPRIS Guidelines: Regulatory Reliance
At its core, the new COFEPRIS agreement, formally known as the “Agreement by which the general guidelines for the application of the abbreviated regulatory pathway for the granting of sanitary registrations of health supplies are issued, in which the requested requirements, tests, and evaluation procedures issued by reference regulatory authorities and the World Health Organization’s prequalification program are recognized as equivalent,” introduces a robust framework of regulatory reliance . This means COFEPRIS will now recognize and leverage the assessments and approvals conducted by other stringent reference regulatory authorities (RRAs) and the World Health Organization (WHO) Prequalification Program. This strategic shift aims to accelerate market access for safe, effective, and quality health products by eliminating redundant evaluations.
Key Provisions and Benefits:
• Accelerated Approval Timelines: The most impactful change is the drastic reduction in approval times. Marketing authorizations may now be granted within 30 business days for medical devices and 45 business days for medicines, a significant improvement from previous timelines that could span years .
• No Duplication of Technical Assessments: Companies with existing approvals from recognized RRAs will no longer need to undergo repetitive technical assessments, streamlining the entire process and reducing the burden on applicants .
• Automatic Recognition: The new pathway allows for the automatic recognition of authorizations issued by high-surveillance regulatory bodies, fostering greater trust and efficiency in the approval process .
• Simplified Procedures: The guidelines explicitly state that COFEPRIS will not request additional documentation or requirements beyond those established in the new framework, unifying criteria and reducing procedural complexities .
Recognized Reference Regulatory Authorities (RRAs) and Eligible Products
The COFEPRIS reliance pathway acknowledges approvals from several leading global regulatory bodies, including:
• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• Swissmedic (Switzerland)
• Health Canada
• Therapeutic Goods Administration (TGA, Australia)
• WHO Prequalification Programme
This broad recognition covers a wide range of eligible products:
• Medicines: This includes generics, innovative biotechnological products, biosimilars, biologicals, and vaccines .
• Medical Devices: Devices of any risk class are eligible, provided they originate from countries participating in the International Medical Device Regulators Forum (IMDRF) or the Medical Device Single Audit Program (MDSAP) .
It is crucial to note that only authorizations granted through standard procedures are eligible. Emergency use authorizations, accelerated, or conditional approvals are explicitly not valid under this new pathway .
Core Requirements for Submission
To leverage this abbreviated pathway, applicants must meet specific submission requirements:
1.Technical Dossier in CTD Format: The dossier must be aligned with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines .
2.Valid Marketing Authorization: A current and valid marketing authorization from a recognized reference authority is essential .
3.Good Manufacturing Practice (GMP) Certificates: Evidence of compliance with GMP standards is required .
4.Certificate of Free Sale: This, along with technical documentation and labeling, must comply with Mexican Official Standards (NOMs) .
5.IMDRF Guidelines Compliance (for Medical Devices): Medical device submissions must demonstrate compliance with IMDRF guidelines .
Strategic Implications for Market Entry in Latin America
This regulatory reform positions Mexico as an increasingly attractive destination for global medical innovation. For companies with existing approvals in the U.S., Europe, Canada, or Australia, this new pathway offers unparalleled advantages:
•Reduced Regulatory Risk and Operational Costs: By avoiding redundant evaluations, companies can significantly lower the financial and operational burden associated with market entry .
•Faster Time to Market: The accelerated approval timelines mean that innovative health products can reach Mexican patients much more quickly, providing a competitive edge .
•Alignment with International Standards: Mexico’s adoption of regulatory reliance aligns its policies with global best practices, enhancing its appeal as a reliable market for international investors .
This move is particularly significant given the size and growth of the Mexican healthcare market. The Mexico Healthcare Market was valued at USD 55.6 billion in 2025 and is projected to grow to USD 71 billion by 2032 . The pharmaceutical market alone is expected to reach USD 38.9 billion by 2034, growing at a CAGR of 6.69% between 2026 and 2034 . Medical device imports reached US$11.4 billion in 2024, indicating a robust demand for advanced medical technologies .
The BioIntell Advantage: Navigating the New Landscape
For foreign healthcare firms, understanding and effectively navigating these new regulatory pathways is paramount to successful market entry. BioIntell, with its deep expertise in the Latin American life sciences and healthcare sectors, offers intelligent advisory and a complete infrastructure to facilitate this process. Our team of veteran CEOs, Regulatory, and Market Intelligence experts can help international organizations leverage these new guidelines to scale successfully in Mexico and beyond.
Whether it’s full launch support, local hosting, M&A advisory, or partner bridging, BioIntell ensures that your innovation reaches the right partners and patients with maximum efficiency and security in this evolving regulatory environment.
Conclusion
The new COFEPRIS abbreviated regulatory pathway represents a monumental step forward for Mexico, fostering innovation and improving access to essential health supplies. For international companies, it’s an opportune moment to strategically expand into one of Latin America’s most dynamic healthcare markets. By embracing regulatory reliance, Mexico is not only streamlining its processes but also solidifying its position as a key player in the global healthcare landscape.
References
[2] ClarkeModet. (2025, August 4). Mexico Opens Abbreviated Pathway for Health Products.
[3] MarkNtel Advisors. (n.d.). Mexico Healthcare Market Size, Trends & Forecast 2026-2032.
[4] IMARC Group. (n.d.). Mexico Pharmaceuticals Market Size & Forecast to 2034.
Read more: dof.gob.mx/nota_detalle.php?codigo=5763319&fecha=18/07/2025